95,386 Shares in Danaher Corporation $DHR Purchased by United Capital Financial Advisors LLC

United Capital Financial Advisors LLC bought a new stake in Danaher Corporation (NYSE:DHR) during the second quarter, HoldingsChannel.com reports. The fund bought 95,386 shares of the conglomerate’s stock, valued at approximately $18,169,000.

Several other hedge funds also recently made changes to their positions in the business. EP Wealth Advisors LLC acquired a new position in Danaher in the 2nd quarter valued at $3,807,000. Northwestern Mutual Wealth Management Co. lifted its holdings in shares of Danaher by 303.7% during the fourth quarter. Northwestern Mutual Wealth Management Co. now owns 248,020 shares of the conglomerate’s stock worth $56,777,000 after buying an additional 186,584 shares in the last quarter. Puzo Michael J bought a new stake in shares of Danaher in the second quarter valued at about $8,624,000. Legal & General Group Plc grew its stake in shares of Danaher by 1.0% in the fourth quarter. Legal & General Group Plc now owns 4,495,287 shares of the conglomerate’s stock valued at $1,029,061,000 after acquiring an additional 43,169 shares in the last quarter. Finally, Madison Asset Management LLC bought a new position in Danaher during the second quarter worth about $85,451,000. 79.05% of the stock is owned by institutional investors.

Analysts Set New Price Targets

A number of research analysts have issued reports on DHR shares. Deutsche Bank Aktiengesellschaft restated a “buy” rating and set a $240.00 target price on shares of Danaher in a research report on Wednesday, July 22nd. Evercore reiterated an “outperform” rating and set a $230.00 target price on shares of Danaher in a research report on Monday, July 6th. HSBC cut their price objective on shares of Danaher from $270.00 to $230.00 and set a “buy” rating for the company in a research report on Wednesday, June 3rd. Citigroup initiated coverage on Danaher in a research note on Tuesday, May 26th. They issued a “buy” rating and a $230.00 price target on the stock. Finally, Wells Fargo & Company cut their price target on Danaher from $212.00 to $195.00 and set an “equal weight” rating on the stock in a research note on Wednesday, July 22nd. One research analyst has rated the stock with a Strong Buy rating, nineteen have assigned a Buy rating and five have assigned a Hold rating to the company’s stock. Based on data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and an average price target of $228.91.

Danaher Price Performance

Danaher stock opened at $215.74 on Friday. The stock has a market capitalization of $151.67 billion, a price-to-earnings ratio of 38.32, a PEG ratio of 2.68 and a beta of 0.78. Danaher Corporation has a 52-week low of $160.93 and a 52-week high of $242.80. The company has a debt-to-equity ratio of 0.48, a quick ratio of 1.25 and a current ratio of 1.65. The stock’s 50 day moving average price is $198.69 and its two-hundred day moving average price is $192.35.

Danaher (NYSE:DHR) last released its quarterly earnings data on Monday, July 20th. The conglomerate reported $1.94 earnings per share for the quarter, beating the consensus estimate of $1.85 by $0.09. Danaher had a net margin of 15.95% and a return on equity of 11.04%. The company had revenue of $6.26 billion during the quarter, compared to analyst estimates of $6.12 billion. During the same quarter in the previous year, the business posted $0.77 EPS. Danaher’s revenue for the quarter was up 5.5% compared to the same quarter last year. On average, equities analysts predict that Danaher Corporation will post 8.53 earnings per share for the current year.

Danaher Company Profile

Danaher Corporation (NYSE: DHR) is a global science and technology company that designs, manufactures and markets products and services for the life sciences, diagnostics, and environmental and applied markets. The company organizes its operations into business segments focused on Life Sciences, Diagnostics, and Environmental & Applied Solutions, supplying instruments, reagents, software and related services that support research, clinical testing, biopharmaceutical development, and industrial and environmental monitoring.

Products and services in Danaher’s portfolio include analytical and diagnostic instruments, laboratory consumables and reagents, digital and software solutions for workflow and data management, field and industrial monitoring equipment, and service and maintenance programs.